Filing Details

Accession Number:
0001144204-17-028639
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-19 16:06:32
Reporting Period:
2017-05-17
Filing Date:
2017-05-19
Accepted Time:
2017-05-19 16:06:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1453687 Selecta Biosciences Inc SELB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055624 A Timothy Springer Harvard Medical School, Ctr
200 Longwood Ave.
Boston MA 02115
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-17 11,244 $14.01 11,244 No 4 P Direct
Common Stock Acquisiton 2017-05-18 4,860 $14.00 16,104 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,237,028 Indirect See Footnote
Common Stock 445,576 Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.64 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. LKST, Inc. is the general partner of Leukon Investments LP. Timothy Springer is the president of LKST, Inc. and the managing member of TAS Partners, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Leukon Investments LP and TAS Partners, LLC except to the extent of his pecuniary interest therein, if any.
  3. Held by Leukon Investments LP.
  4. Held by TAS Partners, LLC.